Prediction of 3 months MTX non-response (DAS28>3.2) in early rheumatoid arthritis
Validation of prediction model to identify DMARD-naïve rheumatoid arthritis patients with high risk of insufficient response to MTX using clinical variables.
Autori della ricerca: Gosselt HR, Verhoeven MMA, de Rotte MCFJ, Pluijm SMF, Muller IB, Jansen G, Tekstra J, Bulatović-Ćalasan M, Heil SG, Lafeber FPJG, Hazes JMW, and de Jonge R.
Versione: 1.31
  • Pubblico
  • Reumatologia
  • {{ modelType }}
  • Dettagli
  • Convalida del modello
  • Salvare l'input
  • Ingresso di carico
  • lang lang

Calcolare il risultato

Impostare altri parametri per eseguire il calcolo

Probability of MTX non-response after 3 months of treatment: %

{{ resultSubheader }}
{{ chart.title }}
Intervallo di risultati {{ additionalResult.min }} a {{ additionalResult.max }}

Informazioni condizionali

How this model should be used: 
This prediction model could assist in identification of insufficient responders at diagnosis. For patients with high probability of insufficient response to MTX, additional biologics or JAK-inhibitors could be prescribed. For those with low probabilities of insufficient response, these expensive treatments could be spared. This distinction at diagnosis could save precious time for insufficient responders, allowing earlier control of disease activity resulting in better long-term outcomes.

Model performance: 
Discriminative power of the model was assessed through evaluating the area under the receiver operating characteristic curve (AUC). The AUC of the model was 0.75 (95% CI: 0.69 – 0.81), indicating that the model correctly classified patients in 75% of the cases.

Goodness-of-fit between the predicted probabilities and observed values was tested using the Hosmer-Lemeshow test. The associated P-value was 0.634, indicating good model fit. 

Decisions on appropriate risk cut-offs:
Taking into consideration the “window of opportunity” for optimal treatment we consider it crucial to adequately treat insufficient MTX responders with additional bDMARDs/tsDMARDs. Therefore, our goal for this prediction model was to identify as many insufficient responders as possible, while at the same time attempting to restrict the use of bDMARDs/tsDMARDs to those patients who really need them, hence to avoid misclassification of sufficient responders. Considering this, a cut-off probability of 70% (of insufficient response) could be chosen.

At this cut-off, 75% of patients classified as insufficient responder match actual insufficient responders (PPV) and could be treated with additional bDMARDs/tsDMARDs. Additionally, at this cut-off 86% of all sufficient responders would be correctly classified as such (specificity) and could be spared additional treatment.

{{ file.classification }}
PRO
Nota
Le note sono visibili solo nel download dei risultati e non vengono salvate da Evidencio.

Questo modello viene fornito a scopo educativo, formativo e informativo. Non deve essere utilizzato a supporto di decisioni mediche o per fornire servizi medici o diagnostici. Leggete il nostro sito completo disclaimer.

Modelli sottostanti Parte di
Commenti
Commento
Inserisci un commento
I commenti sono visibili a chiunque

Feedback del modello

Ancora nessun feedback 1 Commento {{ model.comments.length }} Commenti
Su {{ comment.created_at }} {{ comment.user.username }} un autore non più registrato ha scritto:
{{ comment.content }}
logo

Effettuare l'accesso per abilitare le funzionalità di stampa di Evidencio

Per utilizzare le funzioni di stampa di Evidencio, è necessario aver effettuato il login.
Se non si dispone di un account comunitario Evidencio, è possibile creare un account personale gratuito all'indirizzo:

https://www.evidencio.com/registration

Risultati stampati - Esempi {{ new Date().toLocaleString() }}

Vantaggi del conto comunitario Evidencio

With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

Esclusione di responsabilità: i calcoli da soli non dovrebbero mai dettare la cura del paziente e non sostituiscono il giudizio professionale.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved